Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2 N0 patients with incidental pathologic lymph node metastasis following initial surgery. To investigate the outcomes of adjuvant Sintilimab in patients with locally adva

Trial Details

NCT ID
NCT05495152
Phase
PHASE3
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Sintilimab
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Histologically proven squamous cell carcinoma.
  • Tumours are located in the thoracic oesophagus.
  • Age is between 18 years and 70 years.
  • ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →